AACR21: Sanofi rolls out new da­ta for ear­ly-stage 'non-al­pha' IL-2. Ear­ly feed­back? In­ter­est­ing, but most­ly meh

When Paul Hud­son over at Sanofi inked a $2.5 bil­lion buy­out of can­cer play­er Syn­thorx in late 2019, one of the cen­ter­pieces of the deal was an IL-2 the French drug­mak­er en­vi­sioned as the per­fect part­ner to its im­munother­a­py port­fo­lio. Now, Sanofi is ready to roll out hu­man da­ta for that can­di­date, and the re­sults have earned a re­sound­ing “meh.”

Sanofi’s en­gi­neered “non-al­pha” IL-2 THOR-707 post­ed a mea­ger three par­tial re­spons­es across two co­horts as a monother­a­py and in com­bi­na­tion with Mer­ck’s Keytru­da for a range of ad­vanced or metasta­t­ic sol­id tu­mors, ac­cord­ing to Phase I da­ta pre­sent­ed Sat­ur­day at the vir­tu­al AACR meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER